Review decision – February 2020

Decision to update termination advice in a clinical guideline

NICE was unable to recommend bezlotoxumab for preventing recurrent Clostridium difficile infection as a submission was not provided during the development of the appraisal. Consequently, the appraisal was terminated in September 2019.

The company has confirmed that they have no plans to make a submission to the NICE Technology Appraisal programme for this topic at a later date.

Consequently NICE’s Guidance Executive has decided that the termination advice TA601 should be updated in the forthcoming antimicrobial prescribing guideline for Clostridium difficile infection.

The clinical guideline is due to be published in September 2020. At this point the termination advice in TA601 will be withdrawn.

Review decision paper – February 2020

This page was last updated: 27 February 2020